Skip to main navigation
Skip to content
InMed-logo-01

    Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Capabilities
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
  • Pharmaceutical Programs

  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Cannabinoids in Development
  • Cannabinoid Products

  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • FAQ
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu

    Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Capabilities
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
  • Pharmaceutical Programs

  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Cannabinoids in Development
  • Cannabinoid Products

  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • FAQ
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Subscribe
NASDAQ_Logo

Press Releases

Press Releases

Jul 25, 2022
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
Jul 18, 2022
InMed Announces Appointment of Chief Operating Officer
Jul 12, 2022
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Jun 14, 2022
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
Jun 09, 2022
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
Jun 06, 2022
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
Jun 02, 2022
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
May 13, 2022
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
May 05, 2022
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV
Apr 28, 2022
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 210

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Rare Cannabinoid Manufacturing

Manufacturing

  • Cannabinoid Manufacturing Capabilities
  • IntegraSyn™ - Cannabinoid Manufacturing
  • Baymedica Cannabinoid Biosynthesis

Pharmaceutical Programs

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Cannabinoids in Development

IR Nav

Investor

  • News Releases
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

Products

  • Cannabichromene (CBC)
  • Cannabicitran (CBT)
  • Cannabidivarin (CBDV)

About

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • FAQ
  • Careers
  • Contact

Learn

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabis Treatments for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

Legal Nav

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer

Social icons

  • Find Us On:
  • >
  • >
  • >